Arch Therapeutics (ARTH) Short Interest Ratio & Short Volume

Short interest is the volume of Arch Therapeutics shares that have been sold short but have not yet been closed out or covered. As of May 15th, investors have sold 200 shares of ARTH short. Learn More on Arch Therapeutics' current short interest.

Arch Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 200 shares, an increase of 100.0% from the previous total of 100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the sector of "medical" compare to Arch Therapeutics: EKIMAS Co. (0.02%), InVivo Therapeutics Holdings Corp. (2.27%), Bluejay Diagnostics, Inc. (0.30%), Encision Inc. (0.00%), Dynatronics Co. (0.34%), Motus GI Holdings, Inc. (2.68%), Intelligent Bio Solutions Inc. (4.47%), United American Healthcare Co. (0.01%), Sintx Technologies, Inc. (0.45%), INVO Bioscience, Inc. (0.58%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Enbridge Inc. ($4.29 billion), T-Mobile US, Inc. ($4.17 billion), Charter Communications, Inc. ($3.07 billion), Occidental Petroleum Co. ($2.81 billion), Moderna, Inc. ($2.37 billion), Coinbase Global, Inc. ($2.27 billion), T. Rowe Price Group, Inc. ($1.98 billion), Verisk Analytics, Inc. ($1.94 billion), Extra Space Storage Inc. ($1.88 billion), and Xylem Inc. ($1.61 billion). View all of the most shorted stocks.

Short selling ARTH is an investing strategy that aims to generate trading profit from Arch Therapeutics as its price is falling. ARTH shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Arch Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ARTH, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ARTH, twice per month. The most recent reporting period available is May, 15 2023.